Fundamentals of Biologicals Regulation
Vaccines and Biotechnology Medicines
- Publisher's listprice EUR 130.00
-
54 873 Ft (52 260 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 5 487 Ft off)
- Discounted price 49 386 Ft (47 034 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
54 873 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2
- Publisher Elsevier Science
- Date of Publication 1 November 2025
- ISBN 9780443219887
- Binding Paperback
- No. of pages450 pages
- Size 234x190 mm
- Weight 450 g
- Language English 700
Categories
Long description:
Fundamentals of Biologicals Regulation: Vaccines and Biotechnology Medicines, Second Edition serves as an introduction to the international regulatory arena in which biologicals are developed, offering an overview of processes and insights into the scientific concepts underpinning global regulations. The book provides in-depth coverage of Quality by Design, Combination Products, Quality Target Product Profiles, Risk Management Plans, REMS, and switching from reliance on in vivo to in vitro analytical methods. It reflects new developments and processes accelerated by the COVID-19 vaccine experience, including emergency use authorizations and conditional marking authorizations. New pedagogic elements and case studies have been added to improve learning outcomes.
This book provides multiple levels of readership, with guidance on basic concepts, a detailed look at regulatory challenges, and practical insights into how regulators consider regulatory science and regulatory process issues across various regions, with an emphasis on the European Medicines Agency and the U.S. Food and Drug Administration.
Table of Contents:
"
SECTION I REGULATORY PROCESS
1. Introduction to the Regulatory Process for Biologicals
2. International Regulatory Convergence
3. Quality by Design (QbD) Approach to Discovery and Development
4. Communications and Formal Meetings With Regulators: Focusing on the Process Before Clinical Trial
5. Clinical Trial Authorization and investigational New Drug Applications
6. Marketing Authorization
7. Alternative Regulatory Pathways and Special Programs
8. Variations or Changes to an Approved Application
9. Good ""X"" Practices
10. Audits and Regulatory Compliance inspections
SECTION II REGULATORY SCIENCE
PART I PRECLINICAL
11. Preclinical Safety and Toxicology
12. Preclinical Pharmacology , Proof-of-Principle
13. Institutional Biosafety Committees and Regulation of Genetically Modified Organisms
14. Risk Assessments
PART II PRODUCT
15. Product Construction, Manufacture, and Process Validation
16. Analytical Method Development and Validation Leading to Control Strategy and Lot Release
PART Ill CLINICAL
17. Regulatory Aspects of Clinical Trials
18. Pharmacovigilance and RiskMAPs
19. Clinical Trial Ethics, Human Subjects Protections, and the Informed Consent process
20. Independent Ethics Committees and Institutional Review Boards
SECTION Ill PRODUCT-SPECIFIC REGULATORY PROCESSES
21. Biosimilars
22. In Vitro Diagnostics and Biotech Medical Devices
23. Combination Products
24. Regulatory Policy and Public Health Policy
